ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年12月19日 17時00分
TransCanna Wins 1st and 3rd place at the 2019 Emerald Cup for SolDaze CBD Edibles
Vancouver, BC, 2019年12月19日 - (JCN Newswire) - TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) ("TransCanna" or the "Company") is pleased to announce that SolDaze Snacks won first place for their tropical mango fruit bites and third place for their strawberry mango fruit bites in the CBD edible category at the 2019 Emerald Cup. SolDaze has won multiple times at the Emerald Cup, including in 2018 for its THC edibles.
"We had great customer response to our CBD edibles," stated Shawn Shevlin, manager of the SolDaze brand for TransCanna. "Customers loved the taste, price point and the fact that they are organic and naturally sweetened. It was a great honor to be on the stage and to be recognized by some of the true trailblazers in the cannabis industry."
The Emerald Cup is Northern California's premier cannabis event which advances the concept of sustainable, outdoor farming. The event has a reputation which is firmly solidified as the largest, most-respected, outdoor cannabis competition in the world.
"Congratulations to our team for their hard work to bring these award-winning SolDaze products to market. There is a tremendous upside for TransCanna with our CBD edibles in California and across the US, as the CBD market opens up nationwide," said Steve Giblin, president and CEO of TransCanna. "We have already expanded our distribution network to meet anticipated demand."
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a California based, Canadian listed, company building Cannabis focused brands for the California lifestyle, through its wholly-owned California subsidiaries.
For further information, please visit the Company's website at www.transcanna.com or email the Company at
info@transcanna.com
.
On behalf of the Board of Directors
Steve Giblin
President
604-609-6199
The information in this news release includes certain information and statements about management's view of future events, expectations, plans, and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN
To view the source version of this press release, please visit
https://www.newsfilecorp.com/release/50933
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
The 26th Hong Kong Forum marks successful completion
Dec 03, 2025 22:44 JST
Mitsubishi Motors Launches the All-New Destinator in Vietnam
Dec 03, 2025 18:00 JST
Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Dec 03, 2025 11:30 JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Dec 03, 2025 00:01 JST
NEC Launches AI Agent Service in Japan to Automate Procurement Negotiations Using AI
Dec 02, 2025 23:43 JST
Fujitsu develops new technology to support human-robot collaboration
Dec 02, 2025 23:26 JST
Fujitsu establishes international consortium to tackle disinformation/misinformation and new AI risks
Dec 02, 2025 22:55 JST
Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms
Dec 01, 2025 23:04 JST
Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials
Dec 01, 2025 22:43 JST
Fujitsu launches 'Fujitsu Accelerator Program for SPORTS' to create new value through Sports x Technology
Dec 01, 2025 22:14 JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 28, 2025 23:00 JST
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Nov 28, 2025 19:41 JST
MHI Publishes "MHI REPORT 2025" and "SUSTAINABILITY DATABOOK 2025"
Nov 28, 2025 19:05 JST
Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST
Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST
Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST
NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST
World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST
More Latest Release >>